We believe that specific inflammatory disease profiles may have a predictive role in cancer patients prone to interstitial pneumonia, with anti-RO-52 antibody positivity potentially associated with an increased risk of AIP after cancer treatment. The gene discussed is TRIM21; the disease is cancer.